Martial Lacroix

GeneChem Management Inc (GeneChem) is an independent venture capital firm founded in 1997. The firm is headquartered in Montréal.

Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies.

BioChem ImmunoSystems, Inc. is an investor group led by management.

Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada.

Celmed BioSciences Inc. is a biopharmaceutical company. The company is engaged in developing breakthrough products to treat cancer. The company offers rational drug design and pharmacogenomic concepts to improve cancer patient care. Products of the company include Theralux and NB1011 which offers “Trojan horse solution' to treat cancer. The company is headquartered in Saint-Laurent, Canada.

Cyprotex Ltd. provides pharmaceutical research and development services. It offers ADME and pharmacokinetic, Biosciences, in vitro skin and ocular testing, physicochemical profiling, in vitro toxicology, in silico prediction, and endocrine disruption. The company was founded by David Leahy in 1999 and is headquartered in Abingdon, the United Kingdom.

Osprey Pharmaceuticals USA, Inc. develops protein therapeutics. The firm provides products for the treatment of inflammatory and autoimmune conditions. The company was founded in 2008 and is headquartered in San Francisco, CA

Chlorion Pharma, Inc. Develops small molecule leads for the treatment of naturopathic pain and epilepsy. It develops therapeutics for the treatment of neuropathic pain and epilepsy. The company was founded by Jeffrey A. M. Coull, Yves De Koninck and Martin Gagnon in 2004 and is headquartered in Laval, Canada.

AgeChem Financial, Inc. engages in the provision of investment services, It seeks to invest in companies developing therapeutics targeting age-related diseases. The company was founded in 2006 and is headquartered in Montreal, Canada.